Cargando…

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure

Objectives: To the best of our knowledge, data from Gemtuzumab ozogamicin in Acute Myeloid Leukemia (AML) patients with failure of organ functions and poor performance status are extremely lacking. Moreover, the fast recovery from organ failure, after Gemtuzumab ozogamicin administration, has never...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaytsev, Daniil, Girshova, Larisa, Ivanov, Vladimir, Budaeva, Irina, Motorin, Dmitri, Badaev, Renat, Mirolubova, Julia, Grobovenko, Evgeni, Chitanava, Tamara, Zaykova, Ekaterina, Alexeeva, Julia, Zaritskey, Andrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167863/
https://www.ncbi.nlm.nih.gov/pubmed/32050707
http://dx.doi.org/10.3390/biology9020028
_version_ 1783523604968767488
author Zaytsev, Daniil
Girshova, Larisa
Ivanov, Vladimir
Budaeva, Irina
Motorin, Dmitri
Badaev, Renat
Mirolubova, Julia
Grobovenko, Evgeni
Chitanava, Tamara
Zaykova, Ekaterina
Alexeeva, Julia
Zaritskey, Andrey
author_facet Zaytsev, Daniil
Girshova, Larisa
Ivanov, Vladimir
Budaeva, Irina
Motorin, Dmitri
Badaev, Renat
Mirolubova, Julia
Grobovenko, Evgeni
Chitanava, Tamara
Zaykova, Ekaterina
Alexeeva, Julia
Zaritskey, Andrey
author_sort Zaytsev, Daniil
collection PubMed
description Objectives: To the best of our knowledge, data from Gemtuzumab ozogamicin in Acute Myeloid Leukemia (AML) patients with failure of organ functions and poor performance status are extremely lacking. Moreover, the fast recovery from organ failure, after Gemtuzumab ozogamicin administration, has never been reported. This study aimed to demonstrate the efficacy and rapid response of Gemtuzumab ozogamicin in refractory acute myeloid leukemia (AML) patients with pulmonary and kidney failure and poor performance status. Three refractory AML patients, with organ dysfunction, are described. One patient was pre-treated with intensive chemotherapy, and two other patients progressed during Azacitidine treatment. Two patients had respiratory failure grade 2 and one patient suffered from acute kidney insufficiency. Two patients were highly febrile with an elevated С-Reactive Protein (CRP) level. The WHO performance status of three was measured in all patients. Gemtuzumab ozogamicin administration was performed in three patients, followed by a further switch to Gemtuzumab ozogamicin + Azacitidine or “7+3” treatment. Results: Gemtuzumab ozogamicin administration resulted in abrupt fever cessation in two febrile patients simultaneously with a rapid decrease in CRP level and fast resolution of respiratory failure. Recovery of kidney function was noticed rapidly in patients with renal insufficiency. The WHO performance status was elevated in all three patients. No adverse grade II–III effects were noticed. Further treatment made two patients eligible for intensive chemotherapy, one patient underwent allogeneic stem cell transplantation, and the patient with kidney failure obtained complete remission. Conclusions: Gemtuzumab ozogamicin therapy appeared to be safe and highly efficacious in relapsed/refractory AML patients with organ dysfunction, like pulmonary or renal failure and poor performance status, and may contribute to rapid recovery from organ failures.
format Online
Article
Text
id pubmed-7167863
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71678632020-04-21 Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure Zaytsev, Daniil Girshova, Larisa Ivanov, Vladimir Budaeva, Irina Motorin, Dmitri Badaev, Renat Mirolubova, Julia Grobovenko, Evgeni Chitanava, Tamara Zaykova, Ekaterina Alexeeva, Julia Zaritskey, Andrey Biology (Basel) Case Report Objectives: To the best of our knowledge, data from Gemtuzumab ozogamicin in Acute Myeloid Leukemia (AML) patients with failure of organ functions and poor performance status are extremely lacking. Moreover, the fast recovery from organ failure, after Gemtuzumab ozogamicin administration, has never been reported. This study aimed to demonstrate the efficacy and rapid response of Gemtuzumab ozogamicin in refractory acute myeloid leukemia (AML) patients with pulmonary and kidney failure and poor performance status. Three refractory AML patients, with organ dysfunction, are described. One patient was pre-treated with intensive chemotherapy, and two other patients progressed during Azacitidine treatment. Two patients had respiratory failure grade 2 and one patient suffered from acute kidney insufficiency. Two patients were highly febrile with an elevated С-Reactive Protein (CRP) level. The WHO performance status of three was measured in all patients. Gemtuzumab ozogamicin administration was performed in three patients, followed by a further switch to Gemtuzumab ozogamicin + Azacitidine or “7+3” treatment. Results: Gemtuzumab ozogamicin administration resulted in abrupt fever cessation in two febrile patients simultaneously with a rapid decrease in CRP level and fast resolution of respiratory failure. Recovery of kidney function was noticed rapidly in patients with renal insufficiency. The WHO performance status was elevated in all three patients. No adverse grade II–III effects were noticed. Further treatment made two patients eligible for intensive chemotherapy, one patient underwent allogeneic stem cell transplantation, and the patient with kidney failure obtained complete remission. Conclusions: Gemtuzumab ozogamicin therapy appeared to be safe and highly efficacious in relapsed/refractory AML patients with organ dysfunction, like pulmonary or renal failure and poor performance status, and may contribute to rapid recovery from organ failures. MDPI 2020-02-10 /pmc/articles/PMC7167863/ /pubmed/32050707 http://dx.doi.org/10.3390/biology9020028 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Zaytsev, Daniil
Girshova, Larisa
Ivanov, Vladimir
Budaeva, Irina
Motorin, Dmitri
Badaev, Renat
Mirolubova, Julia
Grobovenko, Evgeni
Chitanava, Tamara
Zaykova, Ekaterina
Alexeeva, Julia
Zaritskey, Andrey
Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
title Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
title_full Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
title_fullStr Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
title_full_unstemmed Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
title_short Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
title_sort rapid efficacy of gemtuzumab ozogamicin in refractory aml patients with pulmonary and kidney failure
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167863/
https://www.ncbi.nlm.nih.gov/pubmed/32050707
http://dx.doi.org/10.3390/biology9020028
work_keys_str_mv AT zaytsevdaniil rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT girshovalarisa rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT ivanovvladimir rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT budaevairina rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT motorindmitri rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT badaevrenat rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT mirolubovajulia rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT grobovenkoevgeni rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT chitanavatamara rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT zaykovaekaterina rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT alexeevajulia rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure
AT zaritskeyandrey rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure